'The biggest inflection point ever': On R&D day, Moderna CEO Stéphane Bancel doubles down on vaccines and lays out a vision for a '40, 50'-drug biotech

Jason Mast

Editor

The stakes have always been different for Moderna. They didn’t invest more in the Covid-19 vaccine race than Pfizer, Sanofi or AstraZeneca, and they didn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'The biggest inflection point ever': On R&D day, Moderna CEO Stéphane Bancel doubles down on vaccines and lays out a vision for a '40, 50'-drug biotech

Jason Mast

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease medicine: ‘We need to sit down with Elon Musk’

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pfizer vet William Pao’s next venture; Sanofi’s computational science exec leaves

Can Bill Anderson save Bayer?

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

How AI can address ongoing challenges in the life sciences industry

'The biggest in­flec­tion point ever': On R&D day, Mod­er­na CEO Stéphane Ban­cel dou­bles down on vac­cines and lays out a vi­sion for a '40, 50'-drug biotech

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'The biggest inflection point ever': On R&D day, Moderna CEO Stéphane Bancel doubles down on vaccines and lays out a vision for a '40, 50'-drug biotech